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Vaginal yeasts in the era of “over the counter”
antifungals
P P Walker, M T Reynolds, H R Ashbee, C Brown, E G V Evans
Objective: To establish whether there has been any rise in the prevalence of non-albicans
Candida species isolated from vaginal swabs since the introduction of “over the counter” antifun-
gal treatments.
Method: A retrospective review looking at all positive vaginal yeast isolates collected from
women attending one genitourinary medicine clinic during the 6 year period from 1993 to 1998
inclusive. All positive vaginal yeast isolates were included, regardless of whether or not the
patients were symptomatic. Isolates from HIV positive women were excluded from the analysis.
Result: No increase in non-albicans vaginal yeast isolates was shown during the period studied.
The proportion of non-albicans yeasts remained constant at approximately 5% of the total yeasts
isolated. The most common non-albicans yeast isolated was C glabrata.
Conclusion: There is no evidence from this study to suggest that the increasing use of “over the
counter” antifungal treatment has selected for atypical, possibly inherently azole resistant, strains
of vaginal yeasts in HIV seronegative women.
(Sex Transm Inf 2000;76:437–438)
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Introduction
It is estimated that 75% of women will experi-
ence at least one episode of vulvovaginal candi-
diasis in their lifetime and 40–50% will experi-
ence two or more episodes.1 Candida albicans
accounts for the majority of cases of vulvovagi-
nal candidiasis, but up to 10% are due to non-
albicans yeast species.2 3
“Over the counter” treatments for vulvovagi-
nal candidiasis have now been licensed for a
number of years. Clotrimazole pessaries were
first made available for purchase by the general
public in 1992 and a fluconazole single dose
oral tablet (“Diflucan One”, Pfizer) in 1995.
Unit pack sales of Diflucan One almost
doubled from 367 115 in 1996 to 661 888 in
1998 (Pfizer Consumer Healthcare, personal
communication). Undoubtedly the availability
of “over the counter” antifungals is convenient
for large numbers of women. However, there is
evidence that many women have diYculty in
diagnosing candidiasis correctly4 and it could
be that increasing or inappropriate use of “over
the counter” preparations might select for
atypical strains of vaginal yeasts.
The aim of this study is to look at yeast
cultures performed on vaginal swabs taken from
women attending a busy genitourinary medicine
clinic to see if there has been any rise in the
prevalence of non-albicans Candida species
found since the introduction of “over the coun-
ter” antifungals.
Methods
This is a retrospective review performed at a
busy city centre genitourinary medicine clinic.
All positive vaginal yeast isolates collected from
women attending between 1993 and 1998
inclusive were included, regardless of whether
or not the patients were symptomatic. Any iso-
lates from HIV seropositive women were
excluded. Any vaginal yeast species isolated
from an individual patient was counted only
once, when first isolated from that patient.
Yeasts isolated from patients were identified
using standard mycological techniques.5 The
purity of cultures was confirmed and each iso-
late was tested for the ability to produce germ
tubes. Germ tube positive isolates were identi-
fied as C albicans.Germ tube negative isolates
were identified using commercially available
kits, including Fongiscreen (Sanofi Pasteur),
API 32C (Bio Merieux), and Auxocolor
(Sanofi Pasteur). If fewer than 10 colonies were
isolated from a patient and they were germ
tube negative, they were not fully identified,
but designated as “non-albicans” yeasts.
Results
No increase in non-albicans vaginal yeast
isolates was shown during the period studied.
The results are detailed in table 1. Of the
women sampled, between 25–27% were cul-
ture positive for yeasts over the 6 years studied.
The non-albicans yeast species found are
Table 1 Vaginal yeast isolates, 1993–8
1993 1994 1995 1996 1997 1998
Total vaginal fungal cultures performed 3950 4400 4484 5265 5427 5646
Total C albicans isolated 946 1069 1126 1240 1381 1456
C albicans <10 CFU* 261 255 273 275 330 385
Total non-albicans Candida isolated (including mixed cultures) 52 61 53 56 61 65
Non-albicans <10 CFU* 19 24 13 22 28 21
Percentage of positive vaginal fungal cultures 25% 26% 26% 27% 27% 27%
Percentage of yeast isolates that were non-albicans 5.2% 5.4% 4.5% 4.3% 4.2% 4.3%
*<10 CFU = fewer than 10 colonies isolated.
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shown in table 2. The proportion of non-
albicans yeasts remained constant at approxi-
mately 5% of the total yeasts isolated. The
most common non-albicans species isolated
was C glabrata, which made up 47–71% of the
non-albicans species that were fully
identified,—that is, more than 10 colonies iso-
lated per swab.
Discussion
Fluconazole resistance is well recognised in
HIV seropositive individuals with oropharyn-
geal and oesophageal candidiasis, and has been
shown to be related to previous fluconazole
exposure.6 In contrast, vulvovaginitis due to
azole resistant C albicans is exceptionally rare in
HIV seronegative women.7 For example, in a
group of women with recurrent vulvovaginal
candidiasis caused by C albicans, no azole
resistance was demonstrated by successive iso-
lates despite at least 6 months’ maintenance
therapy with either oral ketoconazole or fluco-
nazole.8
The use of azole antifungals, particularly flu-
conazole,may also lead to a pathogen shift with
increased incidence of the inherently resistant
Candida species such as C glabrata and C kru-
sei.9 Such a pathogen shift in Candida species
has been observed in bloodstream infections.10
It has been suggested for a number of years that
this may also have occurred in vulvovaginal
candidiasis,11 but so far it has not been demon-
strated except in a very highly selected popula-
tion of women, who were HIV seropositive.12
How many of the women sampled in this
study had previously treated themselves with
antifungal preparations is unknown.
Nevertheless, the study demonstrates that, at
our centre, there has been no increase in the
isolation of non-albicans vaginal yeasts over a 6
year period during which time the use of “over
the counter” antifungals has increased enor-
mously. Thus, so far, we have found no
evidence that the increasing use of these
antifungals has selected for atypical, possibly
inherently azole resistant, strains of vaginal
yeasts in HIV seronegative women.
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Table 2 Non-albicans yeast species isolated, 1993–8
1993 1994 1995 1996 1997 1998
C glabrata 17 24 24 15 20 24
C parapsilosis 3 2 2 5 5 3
S cerevisiae 4 3 3 4 1 6
C tropicalis 1 3 2 3 2 1
C krusei 1 2 2
C lusitaniae 1 1 1 2 3
C famata 1 1
C inconspicua 1 1
C kefyr 2
Trichosporon 1 1 2
Germ tube negative yeasts,
not fully identified* 19 24 13 22 28 21
Mixed species 4 4 5 2 1 5
Total 52 61 53 56 61 65
*If fewer than 10 colonies were isolated from a patient and they were germ tube negative, they were
not fully identified.
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